T. Dai

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

D. Jäger, C. Atreya, E. Van Cutsem, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma.

M. Saif, T. Dai, 2010, JOP : Journal of the pancreas.

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

L. Diaz, C. Atreya, Tae Won Kim, 2018 .

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Daniel T. Fisher, P. Wallace, I. Puzanov, 2022, Frontiers in Oncology.

434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)

R. Yaeger, M. Fakih, D. Hong, 2021, Annals of Oncology.

OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

T. Burns, A. Spira, A. Chiappori, 2022, Journal of Thoracic Oncology.

761 Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 Anti-VISTA antibody in patients with advanced solid tumors

M. Zauderer, R. Martell, R. Noelle, 2022, Regular and Young Investigator Award Abstracts.

1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)

Ruifeng Xu, C. Wang, S. Yang, 2021, Annals of Oncology.

975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma

J. Berlin, M. Blaney, J. Grewal, 2020 .

OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

J. Krauss, C. Langer, K. Marrone, 2022, Journal of Thoracic Oncology.